A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution
0303 health sciences
drug resistance
QH301-705.5
apoptosis
Apoptosis
PIK3CA
synthetic lethality
3. Good health
pooled screening
Proto-Oncogene Proteins p21(ras)
03 medical and health sciences
Cell Line, Tumor
Mutation
KRAS
Humans
BIM
Clustered Regularly Interspaced Short Palindromic Repeats
Biology (General)
Colorectal Neoplasms
CRISPR/Cas9
SRC
Signal Transduction
DOI:
10.1016/j.celrep.2017.07.006
Publication Date:
2017-07-25T18:46:08Z
AUTHORS (22)
ABSTRACT
Combinatorial inhibition of effector and feedback pathways is a promising treatment strategy for KRAS mutant cancers. However, the particular pathways that should be targeted to optimize therapeutic responses are unclear. Using CRISPR/Cas9, we systematically mapped the pathways whose inhibition cooperates with drugs targeting the KRAS effectors MEK, ERK, and PI3K. By performing 70 screens in models of KRAS mutant colorectal, lung, ovarian, and pancreas cancers, we uncovered universal and tissue-specific sensitizing combinations involving inhibitors of cell cycle, metabolism, growth signaling, chromatin regulation, and transcription. Furthermore, these screens revealed secondary genetic modifiers of sensitivity, yielding a SRC inhibitor-based combination therapy for KRAS/PIK3CA double-mutant colorectal cancers (CRCs) with clinical potential. Surprisingly, acquired resistance to combinations of growth signaling pathway inhibitors develops rapidly following treatment, but by targeting signaling feedback or apoptotic priming, it is possible to construct three-drug combinations that greatly delay its emergence.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (59)
CITATIONS (76)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....